Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-1C4D4 maintenance in pancreatic cancer
NCT01608711Phase 2Completed
- Sponsor
- Agensys, Inc.
- Start
- Aug 2012
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of AGS-1C4D4 in pancreatic cancer (PC), sponsored by Agensys, Inc. Primary endpoints: Incidence of adverse events at 31 months and Incidence of anti-AGS-1C4D4 antibody formation. Started Aug 2012; status: completed.
02
Drugs
AGS-1C4D4
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01608711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01608711.